MEA Metaxalone Market

MEA Metaxalone Market Size (2022 to 2027)

The size of the Middle East and Africa Metaxalone Market is projected to grow at a sluggish growth rate during the forecast period.

Metaxalone is a muscle relaxant and a pain reliever, available as a tablet.

Metaxalone is an effective muscle relaxant and pain relief medication for sprains, strains, and other musculoskeletal conditions. Metaxalone is the first choice of athletes for protection against muscle contraction and spam. The increasing number of people who have musculoskeletal disorders such as rheumatoid arthritis is considered one of the driving forces behind the MEA metaxalone market. In addition, the increase in the number of traffic accidents, the high number of surgeries, and the unavailability of adequate healthcare infrastructure have provided many growth opportunities for this market. According to the World Health Organization, approximately 1.35 million people will be injured due to traffic accidents in 2020. Furthermore, the World Health Organization (WHO) estimates around 1.71 billion people will have musculoskeletal disorders in 2022, which will increase the market demand for metaxalone medication.

An increase in the geriatric population across the MEA region will also be a key factor driving the MEA metaxalone market. Older people are prone to fractures, accidents, and sprains, making them the target population. According to the Gulfnews, In Arab countries, the number of people aged 65 and over is anticipated to reach 19.66 million by 2020, increasing 5%. The highest percentage of this age group among Arab countries is estimated to be in the United Arab Emirates with 9%, and the lowest was recorded in Yemen with 3%. Additionally, the rise in chronic low back pain prevalence is projected to drive the market in the near future. According to the WHO, the lifetime prevalence of non-specific low back pain is estimated at between 60% and 70%.

With an increasing number of gym establishments for athletes with an ever-increasing appeal for fitness in the developed and developing, the MEA metaxalone market is poised to grow with an impressive growth rate during the forecast period.

However, the metaxalone medicine had some side effects such as headache, irritability, nausea, and vomiting, which makes it less preferable by patients. Additionally, administration of metaxalone with any other central nervous system depressant may cause central nervous system depression in the patient. All these factors may have a negative impact on the MEA metaxalone market.

This research report on the MEA metaxalone market has been segmented and sub-segmented into the following categories.

By Indication:

• Bone Pain
• Muscle Pain            
• Tunnel Syndrome
• Joint Pain 
• Others     

By End User:

• Hospitals
• Clinics
• Others

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle Eastern region is considered the most lucrative market for metaxalone due to the development in the healthcare system. In 2022, the Saudi Arabian market dominated the market and will continue with this trend over the forecast period. The market growth can be attributed to several factors such as the growing number of older people, advancement of the pharmaceutical industry, increase in the number of surgical procedures, and the use of metaxalone for pain management. In addition, the increase in the number of cosmetic surgeries, rising incomes, and better access to medical care with more hospitals are driving the market's growth.

Regional markets in the United Arab Emirates, Qatar, and Oman will experience steady growth owing to the growing appeal of athletics and the gym, the expansion activities of major players, and the wide availability of the medication. In addition, the tightening of drug prescription rules by the World Health Organization and local government agencies has opened substantial market opportunities for metaxalone.

KEY MARKET PLAYERS:

Some of the key players dominating this market include Biosynth, Chunghwa Chemical Synthesis and Biotech, Sigma Aldrich, CDI Technology, Angelini, Pfizer, Aurum Pharmatech, Finetech Industry Limited, Biochem, and Oxchem Corporation.